Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, Dasbach EJ, Carides GW, Dickstein K, Riegger G, Camm AJ, Martinez FA, Bradstreet DC, Ikeda LS, Santoro EP; ELITE II Investigators. Konstam MA, et al. Am Heart J. 2005 Jul;150(1):123-31. doi: 10.1016/j.ahj.2004.10.035. Am Heart J. 2005. PMID: 16084158 Clinical Trial.
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Poole-Wilson PA, et al. Lancet. 2003 Jul 5;362(9377):7-13. doi: 10.1016/S0140-6736(03)13800-7. Lancet. 2003. PMID: 12853193 Clinical Trial.
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Pitt B, et al. J Card Fail. 1999 Jun;5(2):146-54. doi: 10.1016/s1071-9164(99)90037-4. J Card Fail. 1999. PMID: 10404354 Clinical Trial.
Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole-Wilson PA, Ponikowski P; FAIR-HF committees and investigators. Anker SD, et al. Eur J Heart Fail. 2009 Nov;11(11):1084-91. doi: 10.1093/eurjhf/hfp140. Eur J Heart Fail. 2009. PMID: 19875408 Free PMC article. Clinical Trial.
Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Anker SD, et al. N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17. N Engl J Med. 2009. PMID: 19920054 Free article. Clinical Trial.
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.
Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR; ESSENTIAL Investigators. Metra M, et al. Eur Heart J. 2009 Dec;30(24):3015-26. doi: 10.1093/eurheartj/ehp338. Eur Heart J. 2009. PMID: 19700774 Free PMC article. Clinical Trial.
528 results